New Launch28 Jun 2024, 09:10 pm
Orchid Pharma & Cipla Partner to Launch Antibiotic Cefepime-Enmetazobactam in India
AI Summary
Orchid Pharma Ltd, in partnership with Cipla, has launched a new antibiotic - Cefepime-Enmetazobactam, approved for treating complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP), and Ventilator-Associated Pneumonia (VAP) indications. This strategic alliance aims to combat the rising threat of antimicrobial resistance (AMR) in India. The partnership combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network, ensuring rapid and efficient distribution of the life-saving medication across India.
Key Highlights
- Orchid Pharma and Cipla collaborate to launch Cefepime-Enmetazobactam in India.
- The new antibiotic is designed to address the rising threat of antimicrobial resistance (AMR).
- The partnership leverages Orchid's innovative drug development capabilities and Cipla's extensive distribution network.
- Cefepime-Enmetazobactam is approved for treating cUTI, HAP, and VAP indications.
- Both companies are committed to responsible antibiotic stewardship and appropriate use of the new antibiotic combination.